With the Yabao partnership, Lupin builds on a toehold gained through the Foncoo tie-up as it attempts to scale the market behind the Great Wall of China. Scrip takes a look at possible approaches and potential of the partnership

Lupin has built on a recent alliance in China with Foncoo by agreeing a further partnership for the Chinese market, this time with Yabao Pharmaceutical.

Clinical studies in hiatus, marketing on hold, demand directionless and supply disrupted. Pharma firms in China say it’s likely the good old days may never come back.

The future for glucokinase activation is looking brighter after fresh data on vTv’s oral adjunct to insulin therapy in type 1 diabetes.